C4 Therapeutics (CCCC) vs Precision BioSciences (DTIL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Precision BioSciences (DTIL) has outperformed C4 Therapeutics (CCCC) over the past year, gaining 48.0% versus a gain of 1.6%. Over five years, CCCC leads with a -93.2% price change compared with -97.2% for DTIL. C4 Therapeutics is the larger company by market cap ($325.7 million vs $282.5 million), about 1.2 times the size.
Precision BioSciences converts more of its revenue into profit, with a net margin of -133.4% versus -292.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CCCC | DTIL |
|---|---|---|
| Share price | $2.48 | $7.40 |
| Market cap | $325.67M | $282.46M |
| 1-day change | +1.64% | +7.09% |
| YTD return | +29.84% | +77.88% |
| 1-year return | +1.64% | +48.00% |
| 5-year return | -93.23% | -97.23% |
| P/E ratio (TTM) | — | 29.60 |
| EPS (TTM) | $-0.63 | $0.25 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $35.95M | $34.26M |
| Revenue growth (YoY) | +1.02% | -50.12% |
| Net income (latest FY) | $-104.99M | $-45.72M |
| Operating margin | -320.53% | -152.19% |
| Net margin | -292.08% | -133.45% |
| 52-week high | $5.17 | $11.29 |
| 52-week low | $1.69 | $3.53 |
| Distance from 52-week high | -52.03% | -34.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +404.03% | +297.30% |
| Average volume | 2.57M | 319.79K |
| Shares outstanding | 131.32M | 38.17M |
| Employees | 104 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DTIL has outperformed CCCC by 46.4 percentage points over the past year.
- Precision BioSciences is more profitable, keeping -133.4 cents of every revenue dollar as net income versus -292.1 cents for C4 Therapeutics.
- C4 Therapeutics grew revenue faster in its latest fiscal year (+1.02% vs -50.12%).
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 104 employees
About Precision BioSciences
DTIL stock →Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 69 employees
CCCC vs DTIL FAQ
Which is bigger, C4 Therapeutics or Precision BioSciences?
C4 Therapeutics (CCCC) is larger, with a market capitalization of $325.67M compared with $282.46M for Precision BioSciences (DTIL).
Which stock has performed better over the past year, CCCC or DTIL?
DTIL returned +48.00% over the past 12 months, compared with +1.64% for CCCC (price return, excluding dividends). Past performance does not predict future results.
Are C4 Therapeutics and Precision BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.